FDA approves first drug for type 1 narcolepsy and greenlights mRNA flu vaccine; AstraZeneca and BMS deny merger talks

The U.S. Food and Drug Administration has granted approval for the first therapy specifically targeting type 1 narcolepsy, marking a milestone for patients with this rare sleep disorder.

In a separate decision, the agency also cleared an mRNA‑based influenza vaccine, expanding the use of messenger RNA technology beyond COVID‑19.

Separately, pharmaceutical giants AstraZeneca and Bristol‑Myers Squibb confirmed that there are no ongoing merger discussions between the two companies.